Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EMN 2021

European Myeloma Network (EMN)
March 3–6, 2021

The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.

Experts in the field came together online to discuss and debate the latest updates in the field.

Explore all the latest in myeloma below!

Latest Updates

View all
2:08
Monoclonal antibody therapies for multiple myeloma
Mattia D'Agostino • 26 Feb 2021
1:04
Real-world findings of MRD by MFC in AML
Bruno Paiva • 24 Feb 2021
5:12
Latest developments in the treatment of smoldering myeloma
Niccolò Bolli • 25 Feb 2021
5:40
Role of the microenvironment in myeloma precursor states
Niccolò Bolli • 25 Feb 2021

MRD

View all
2:09
DART4MM: daratumumab in myeloma patients with VGPR to first-line therapy
Alessandro Gozzetti • 24 Feb 2021
1:55
MRD monitoring for myeloma
Bruno Paiva • 24 Feb 2021

Real-World Data

View all
2:00
Real-world data: KRd in R/R multiple myeloma
Elena Zamagni • 2 Mar 2021
3:11
Long-term control of myeloma treated with MABs at second relapse
Uros Markovic • 26 Feb 2021

Immuno-Oncology

View all
1:23
ANCHOR: melflufen plus dexamethasone with bortezomib or daratumumab in myeloma
Enrique Ocio • 19 Feb 2021
2:08
Monoclonal antibody therapies for multiple myeloma
Mattia D'Agostino • 26 Feb 2021

Trial Updates

View all
3:03
Long-term follow-up of ibrutinib in Waldenström’s macroglobulinemia
Steven Treon • 3 Mar 2021
3:08
Frailty subgroup analysis of the MAIA trial
Gordon Cook • 2 Mar 2021
The content of VJHemOnc is intended for healthcare professionals